Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Scholar Rock Holding CorporationNASDAQ: SRRK

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 132.37M shares rose 16.4% year over year, ahead of the +15.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.4% holds above the trailing-twelve-month pace of +15.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
132.37M+1.3% QoQ
Last fiscal yearDec 2025
114.7M+14.9% YoY
LTMSep 2026
126.24M+15.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.4%——
1 year+14.9%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
114.7M USD
Year-over-year change
+14.9%
4-year CAGR
+33.0%

Weighted Avg Shares vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 weighted avg shares of 126.24M shares is the 4th highest of the 11 companies compared; the peer median is 96.75M shares.
  • Its year-over-year change of +15.3% is the 4th highest of 11, against a peer median of +6.0%.
  • Over three fiscal years its annual growth of +24.4% compares with a peer median of +9.8%.
SRRK Competitors Peer median
Weighted Avg Shares for SRRK and competitors
Company Period LTM YoY 3-year CAGR
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
SRRKScholar Rock Holding CorporationLTM Sep 2026126.24M +15.3%+24.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.26M +16.4%+12.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026102.01M +6.4%+6.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
EWTXEdgewise Therapeutics, Inc.LTM Sep 202679.43M -20.2%+24.3%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +5.0%+15.0%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
Peer median (excluding SRRK) 96.75M+6.0%+9.8%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.82M33.19M000
Cost of Revenue108.47M123.04M2.84M1.94M208.44M
Gross Profit(89.65M)(89.85M)(2.84M)(1.94M)(208.44M)
Gross Margin-476.5%-270.7%———
Research & Development108.47M124.44M119.06M182.61M208.44M
Selling, General & Admin40.27M42.62M49.4M67.5M176.21M
Operating Expenses40.27M44.52M168.45M250.12M176.21M
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
EBITDA(129.17M)(129.48M)(162.95M)(237.52M)(369.39M)
EBITDA Margin-686.5%-390.1%———
Operating Income(129.92M)(134.37M)(171.3M)(252.05M)(384.65M)
Operating Margin-690.5%-404.8%———
Interest Income00012.68M13.9M
Interest Expense0006.84M6.89M
Other Income / Expenses(1.88M)(132K)5.51M5.76M6.71M
Income Before Tax(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Pre-Tax Margin-700.5%-405.2%———
Income Tax Expense00000
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Net Margin-700.5%-405.2%———
EPS (Basic)(3.59)(2.21)(1.99)(2.47)(3.29)
EPS (Diluted)(3.59)(2.21)(1.99)(2.47)(3.29)
Weighted Avg Shares36.71M59.61M75.98M99.84M114.7M
Weighted Avg Shares (Diluted)36.71M59.61M75.98M99.84M114.7M

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.